# Adjuvant Therapy of Pegylated Interferon- 2b Plus Melanoma Peptide Vaccine

> **NCT00861406** · PHASE1 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 38 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** Pegylated Interferon-Alfa 2b (PEG Intron)
- **DRUG:** GP-100 Peptide Vaccine

## Key facts

- **NCT ID:** NCT00861406
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-03-10
- **Primary completion:** 2017-02-24
- **Final completion:** 2017-02-24
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2017-03-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00861406

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00861406, "Adjuvant Therapy of Pegylated Interferon- 2b Plus Melanoma Peptide Vaccine". Retrieved via MORVS 2026-10-23 from https://api.morvs.ai/clinical/NCT00861406. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*